


Express Mail Label No. EV213312245US

Date of Deposit: April 1, 2004

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

By:   
Amelia Weintraub

Attorney Docket No. 1012E-102902US  
Client Ref. No. SJK/FP6148191

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Varela-Nieto, Isabel, et al.

Examiner: Grun, J.

Application No.: not yet known

Art Unit: 1641

Filed: April 1, 2004

For: MATERIALS AND METHODS  
RELATING TO ANTI-  
INOSITOLPHOSPHOGLYCAN  
ANTIBODIES

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR § 1.97 and  
§ 1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 10/439,851 filed May 15, 2003. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 10/439,851 filed May 15, 2003 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner.

It is respectfully requested that the cited information on the attached 1449 form be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Emily M. Haliday".

Emily M. Haliday, J.D., Ph.D.  
Reg. No. 38,903

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877

Substitute for form 1449A-B/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Date Submitted	April 1, 2004
	Application Number	Not yet known
	Filing Date	April 1, 2004
	First Named Inventor	Varela-Nieto, Isabel
	Group Art Unit	1641
	Examiner Name	Grun, J.
Attorney Docket Number	1012E-102902US	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	1	WO	96/29425			03/20/1996		
	2	WO	98/10791			09/11/1997		
	3	WO	98/11116			09/11/1997		
	4	WO	98/11117			09/11/1997		
	5	WO	98/11435			09/11/1997		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	6	Campbell, 1984. Monoclonal Antibody Technology, Elsevier, Amsterdam. Pp. 1-4 and 29.	
	7	Caro, H.N. et al., "Isolation and Partial Characterization of Insulin-Mimetic Inositol Phosphoglycans from Human Liver" Biochemical and Molecular Medicine 61:214-228 (1997)	
	8	Farese, et al., 1994, Insulin-induced activation of glycerol-3-phosphate acyltransferase by a chiro-inositol-containing insulin mediator is defective in adipocytes on insulin-resistant, type II diabetic, Goto-Kakizaki rats. Proc. Natl. Acad. Sc. USA 91:11040-11044	
	9	Fonteles, et al., 1996 Infusion of pH 2.0 D-chiro-inositol glycan insulin putative mediator normalizes plasma glucose in streptozotocin diabetic rats at a dose equivalent to insulin without inducing hypoglycaemia. Diabetologia 39: 731-734.	
	10	Huang, et al., "Chiroinositol Deficiency and Insulin Resistance. III. Acute Glycogenic and Hypoglycemic Effects of Two Inositol Phosphoglycan Insulin Mediators in Normal and Streptozotocindabetic Rats in Vivo," Endocrinology 132 (2):652-657 (1993)	
	11	Jones, et al., Biochem and Biophys. Res. Comm. 233:432-437, 1997	
	12	Maurer et al., 1980 Proteins and polypeptides as antigens. Meth. Enzymology 70:29-70.	
	13	Nazih-Sanderson, et al, Biochim. Biophys. Acta, 1346: 45-60, 1997	
	14	Nestler, et al., "Insulin Mediators are the Signal Transduction System Responsible for Insulin's	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	Date Submitted	<b>April 1, 2004</b>
	Application Number	<b>Not yet known</b>
	Filing Date	<b>April 1, 2004</b>
	First Named Inventor	<b>Varela-Nieto, Isabel</b>
	Group Art Unit	<b>1641</b>
	Examiner Name	<b>Grun, J.</b>
	Attorney Docket Number	<b>1012E-102902US</b>

		Actions on Human Placental Steroidogenesis", Endocrinology 129(6):2951-2956 (1991)	
	15	Represa, Juan, et al., "Glycosyl-phosphatidylinositol/inositol phosphoglycan: A signaling system for the low-affinity nerve growth factor receptor" Proc. Natl. Acad. Sci. USA 88:8016-8019 (September 1991)	
	16	Romero, Guillermo, et al., "Anti-inositolglycan antibodies selectively block some of the actions fo insulin in intact BC3H1 cells" Proc. Natl. Acad.Sci.USA 87:1476-1480 (February 1990)	
	17	Shashkin, et al., 1997. Insulin mediators in man: effects of glucose ingestion and insulin resistance. Diabetologia 40:557-563.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.